3 weeks Gilead Stock Rises 8% Post Q4 Earnings: Should You Buy or Sell? Zacks

GILD’s strong HIV portfolio should maintain momentum for the company. The guidance for 2025 is impressive. We believe there is more room for growth and recommend the stock to investors.